TaiMed Biologics

TaiMed Biologics Inc. is a biotechnology company. The company has developed Ibalizumab, a monoclonal antibody (mAb) and an HIV viral entry inhibitor treatment. The company is committed to discovering, developing, and delivering drugs primarily for HIV in Taiwan. It leverages its intellect, extensive expertise, and management resources to develop a robust healthcare product pipeline that benefits patients, rewards investors, and drives prominence in the biotechnology industry. The company's product portfolio includes TMB-355, a Phase IIb viral entry inhibitor that blocks HIV with a humanized mAb treatment.